Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–10 of 10 results
Advanced filters: Author: Bart A. Westerman Clear advanced filters

  • Drug synergies impact the efficacy of combination therapies but are difficult to identify. Here Narayan et al. describe the drug atlas, a method to predict effective drug combinations from common exclusive drug effects providing a resource for exploring and understanding effective drug combinations.

    • Ravi S. Narayan
    • Piet Molenaar
    • Bart A. Westerman
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-14

  • The GLASS Consortium studies the evolutionary trajectories of 222 patients with a diffuse glioma to aid in our understanding of tumour progression and treatment failure

    • Floris P. Barthel
    • Kevin C. Johnson
    • Roel G. W. Verhaak
    Research
    Nature
    Volume: 576, P: 112-120

  • Isocitrate dehydrogenase 1/2 mutant (IDHmt) astrocytomas are characterized by a scarcity of T cells, but their phenotypes and functionality are lesser known. Here authors provide an integrative approach to describe the immune microenvironment of these tumors and show that gemistocytic tumor cells, a cell type abundant in the tumor stroma surrounding perivascular T cell accumulations, generate a glial scarring-like functional state, responsible for T cell exclusion.

    • Levi van Hijfte
    • Marjolein Geurts
    • Reno Debets
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-16

  • Resistance to first line treatment is a major hurdle in cancer treatment, that can be overcome with drug combinations. Here, the authors provide a large drug combination screen across cancer cell lines to benchmark crowdsourced methods and to computationally predict drug synergies.

    • Michael P. Menden
    • Dennis Wang
    • Julio Saez-Rodriguez
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-17

  • The IDG-DREAM Challenge carried out crowdsourced benchmarking of predictive algorithms for kinase inhibitor activities on unpublished data. This study provides a resource to compare emerging algorithms and prioritize new kinase activities to accelerate drug discovery and repurposing efforts.

    • Anna Cichońska
    • Balaguru Ravikumar
    • Tero Aittokallio
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-18

  • Rogier Versteeg, Johan van Nes and colleagues report that neuroblastomas comprise two cell types, mesenchymal and adrenergic, that have different responses to chemotherapeutic agents in vitro. Using ChIP–seq and expression profiling of pairs of phenotypically divergent isogenic cell lines, they identify candidate transcription factors for regulation of the two cell states.

    • Tim van Groningen
    • Jan Koster
    • Rogier Versteeg
    Research
    Nature Genetics
    Volume: 49, P: 1261-1266